News

The vice president and chief medical officer of the Neurology Business Group at Eisai discussed the company's decision to continue efforts on amyloid therapy despite prior setbacks.

Catch up on some of our most popular video interviews with leaders in the field, including discussions with Imad Najm, MD, James Leverenz, MD, Richard Isaacson, MD, and more.

The director of Infantile Spasms Program at UCLA Mattel Children’s Hospital discussed why learning more about patients with infantile spasms may lead to further breakthroughs on the origins of autism spectrum disorder.

After promising results in prior phase 2 study, Stealth BioTherapeutics’ elampretide has failed to show change in the 6-minute walk test and Primary Mitochondrial Myopathy Symptom Assessment total fatigue score in the MMPOWER-3 trial.

The professor of neurology at NYU Langone spoke to her clinical experience with cenobamate and how she anticipates it might be utilized once it becomes commercially available.

A greater understanding of the role of the immune system in movement disorders may illuminate a path to treatments that target the central causes of disease.

The behavioral director at the Angelman Syndrome Clinic at Massachusetts General Hospital offered insight into the challenges in studying a drug, such as gaboxadol, in Angelman syndrome.

The staff epileptologist at Cleveland Clinic’s Epilepsy Center spoke to her experience using telemedicine to manage patients with epilepsy and some of the unexpected perspectives it offers.

Karl Doghramji, MD, medical director of the Jefferson Sleep Disorders Center, reviews optimal management strategies for elderly patients with insomnia disorder.

The medical director of the Comprehensive Stroke Center at Cleveland Clinic detailed the differences between neuroprotection and neurorestoration, and the available options for each.

An in-depth analysis of the genetics of DMD and disease modifiers such as the NF-kB pathway in patients with Duchenne muscular dystrophy.

Branded as Ubrelvy, Allergan’s oral calcitonin gene-related peptide antagonist is the first-in-class to be approved for this indication.

Panelists review the delicate process of introducing a new medication to a treatment regimen and the creative endeavors employed to improve adherence.

The director of Infantile Spasms Program at UCLA Mattel Children’s Hospital detailed his personal experience counseling parents whose first child has infantile spasms.

The small-molecule dual orexin receptor antagonist was approved based on data from 2 pivotal phase 3 studies which showed statistical superiority over placebo for sleep onset latency.

The behavioral director at the Angelman Syndrome Clinic at Massachusetts General Hospital discussed the phase 3 NEPTUNE trial of gaboxadol, also known as OV101.

The professor of neurology at NYU Langone discussed cenobamate’s potential as a treatment option for patients who have uncontrolled seizures, as well as its ability to bring a high number of patients toward complete seizure freedom.

Neurology News Network for the week ending December 21, 2019.

Two lots of the oral seizure treatment have been recalled and should be returned to the manufacturer.

After resubmitting the NDA for apomorphine sublingual film (APL-130277), the FDA has set the new PDUFA action date of May 21, 2020.

The drug safety warning stems from a review of case reports and clinical studies that showed use of gabapentinoids with or without opioids is associated with serious breathing difficulties.